Mostrar el registro sencillo del ítem

dc.contributor.authorPera, Marta
dc.contributor.authorLarrea, Delfina
dc.contributor.authorGuardia-Laguarta, Cristina
dc.contributor.authorMontesinos, Jorge
dc.contributor.authorVelasco, Kevin R.
dc.contributor.authorAgrawal, Rishi R
dc.contributor.authorXu, Yimeng
dc.contributor.authorChan, Robin B.
dc.contributor.authorDi Paolo, Gilbert
dc.contributor.authorMehler, Mark F.
dc.contributor.authorPerumal, Geoffrey S.
dc.contributor.authorMacaluso, Frank P.
dc.contributor.authorFreyberg, Zachary Z.
dc.contributor.authorAcin-Perez, Rebeca 
dc.contributor.authorEnriquez, Jose Antonio 
dc.contributor.authorSchon, Eric A.
dc.contributor.authorArea-Gómez, Estela
dc.date.accessioned2018-10-19T08:00:41Z
dc.date.available2018-10-19T08:00:41Z
dc.date.issued2017
dc.identifierISI:000415184300008
dc.identifier.citationEMBO J. 2017; 36(22):3356-3371
dc.identifier.issn0261-4189
dc.identifier.urihttp://hdl.handle.net/20.500.12105/6492
dc.description.abstractIn the amyloidogenic pathway associated with Alzheimer disease (AD), the amyloid precursor protein (APP) is cleaved by beta-secretase to generate a 99-aa C-terminal fragment (C99) that is then cleaved by c-secretase to generate the beta-amyloid (Ab) found in senile plaques. In previous reports, we and others have shown that c-secretase activity is enriched in mitochondria-associated endoplasmic reticulum (ER) membranes (MAM) and that ER-mitochondrial connectivity and MAM function are upregulated in AD. We now show that C99, in addition to its localization in endosomes, can also be found in MAM, where it is normally processed rapidly by c-secretase. In cell models of AD, however, the concentration of unprocessed C99 increases in MAM regions, resulting in elevated sphingolipid turnover and an altered lipid composition of both MAM and mitochondrial membranes. In turn, this change in mitochondrial membrane composition interferes with the proper assembly and activity of mitochondrial respiratory supercomplexes, thereby likely contributing to the bioenergetic defects characteristic of AD.
dc.description.sponsorshipWe thank Drs. Orian Shirihai and Marc Liesa (UCLA) for assistance with the Seahorse measurements, Dr. Huaxi Xu (Sanford Burnham Institute) for the APP-DKO MEFs and Dr. Mark Mattson (NIH) for the PS1 knock-in mice, Drs. Arancio and Teich for the APP-KO mice tissues used in these studies, Dr. Hua Yang (Columbia University) for mouse husbandry, and Drs. Marc Tambini, Ira Tabas, and Serge Przedborski for helpful comments. This work was supported by the Fundacion Alfonso Martin Escudero (to M.P.); the Alzheimer's Drug Discovery Foundation, the Ellison Medical Foundation, the Muscular Dystrophy Association, the U.S. Department of Defense W911NF-12-1-9159 and W911F-15-1-0169), and the J. Willard and Alice S. Marriott Foundation (to E.A.S.); the U.S. National Institutes of Health (P01-HD080642 and P01-HD032062 to E.A.S.; NS071571 and HD071593 to M.F.M.; R01-NS056049 and P50-AG008702 to G.D.P.; 1S10OD016214-01A1 to G.S.P. and F.P.M, and K01-AG045335 to E.A.-G.), the Lucien Cote Early Investigator Award in Clinical Genetics from the Parkinson's Disease Foundation (PDF-CEI-1364 and PDF-CEI-1240) to C.G.-L., and National Defense Science and Engineering Graduate Fellowship (FA9550-11-C-0028) to R.R.A.
dc.language.isoeng
dc.publisherWiley 
dc.type.hasVersionVoR
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectAlzheimer's disease
dc.subjectC99
dc.subjectMAM
dc.subjectMitochondria and sphingolipids
dc.subjectAMYLOID PRECURSOR PROTEIN
dc.subjectC-TERMINAL FRAGMENT
dc.subjectBETA-SECRETASE ACTIVITY
dc.subjectENDOPLASMIC-RETICULUM
dc.subjectMOUSE MODEL
dc.subjectOXIDATIVE STRESS
dc.subjectTRANSGENIC MICE
dc.subjectLIPID RAFTS
dc.subjectA-BETA
dc.subjectSYNAPTIC MITOCHONDRIA
dc.titleIncreased localization of APP-C99 in mitochondria-associated ER membranes causes mitochondrial dysfunction in Alzheimer disease
dc.typejournal article
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID29018038
dc.format.volume36
dc.format.page3356-3371
dc.identifier.doi10.15252/embj.201796797
dc.contributor.funderFundación Alfonso Martín Escudero 
dc.contributor.funderAlzheimer's Drug Discovery Foundation
dc.contributor.funderEllision Medical Foundation
dc.contributor.funderMuscular Dystrophy Association 
dc.contributor.funderUnited States Department of Defense 
dc.contributor.funderJ. Willard and Alice S. Marriott Foundation 
dc.contributor.funderNational Institutes of Health (Estados Unidos) 
dc.contributor.funderParkinson's Disease Foundation
dc.description.peerreviewed
dc.identifier.e-issn1460-2075
dc.relation.publisherversionhttps://doi.org/10.15252/embj.201796797
dc.identifier.journalEMBO Journal
dc.repisalud.orgCNICCNIC::Grupos de investigación::Genética Funcional del Sistema de Fosforilación Oxidativa
dc.repisalud.institucionCNIC
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución 4.0 Internacional